deinoxanthin: isolated from Deinococcus radiodurans; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16061289 |
| CHEBI ID | 80464 |
| MeSH ID | M0544462 |
| Synonym |
|---|
| deinoxanthin |
| LMPR01070182 |
| CHEBI:80464 |
| (5r)-5-hydroxy-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-24-hydroxy-3,7,12,16,20,24-hexamethylpentacosa-1,3,5,7,9,11,13,15,17,19,21-undecaenyl]-2,4,4-trimethylcyclohex-2-en-1-one |
Deinoxanthin (DX) is a unique carotenoid synthesized by Deinococcus radiodurans. It is one of the most radioresistant organisms known.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Deinoxanthin (DX) is a unique carotenoid synthesized by Deinococcus radiodurans, one of the most radioresistant organisms known. " | ( Insight into the strong antioxidant activity of deinoxanthin, a unique carotenoid in Deinococcus radiodurans. Ji, HF, 2010) | 2.06 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Deinoxanthin treatment caused an increase in ROS in all tested cells, suggesting possible pro-oxidant activity of deinoxanthin." | ( Induction of apoptosis by deinoxanthin in human cancer cells. Choi, JI; Choi, YJ; Hur, JM; Jo, M; Kim, DH; Lim, S, 2014) | 1.42 |
| Class | Description |
|---|---|
| xanthophyll | A subclass of carotenoids consisting of the oxygenated carotenes. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.99) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (6.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||